- Home
- ACXP
as 01-17-2025 4:00pm EST
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | STATEN ISLAND |
| Market Cap: | 31.4M | IPO Year: | 2021 |
| Target Price: | $12.00 | AVG Volume (30 days): | 455.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.68 - $4.15 | Next Earning Date: | 03-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Acurx Pharmaceuticals Inc. (ACXP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LUCI DAVID P | ACXP | President and CEO | Jan 6 '25 | Buy | $1.02 | 49,261 | $49,999.91 | 1,097,458 | |
| Sailer Carl | ACXP | Director | Jan 6 '25 | Buy | $1.02 | 24,631 | $25,000.46 | 137,183 | |
| DELUCCIA ROBERT J | ACXP | Director10% Owner | Jan 6 '25 | Buy | $1.02 | 49,261 | $49,999.91 | 1,010,196 | |
| Scodari Joseph C | ACXP | Director | Jan 6 '25 | Buy | $1.02 | 24,631 | $25,000.46 | 27,708 | |
| Donohue James J. | ACXP | Director | Jan 6 '25 | Buy | $1.02 | 9,852 | $9,999.78 | 22,352 | |
| DEAN JACK H | ACXP | Director | Jan 6 '25 | Buy | $1.02 | 9,852 | $9,999.78 | 21,776 |
Latest Acurx Pharmaceuticals Inc. News
ACXP Breaking Stock News: Dive into ACXP Ticker-Specific Updates for Smart Investing
PR Newswire
11 days ago
Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MT Newswires
12 days ago
Acurx Launches $2.5 Million Registered Direct Offering; Shares Fall After-Hours
PR Newswire
12 days ago
Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
PR Newswire
13 days ago
Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)
Zacks
15 days ago
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
ACCESSWIRE
a month ago
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025
PR Newswire
a month ago
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications
Zacks
2 months ago
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now
Compare ACXP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACXP Acurx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.